Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05852873 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway

Study acronym: PanoramicNOR
StatusActive, Not Recruiting
PhasePhase 3
Started2023-05-12
View on ClinicalTrials.gov ↗

Amendment history

2025-11-18
Recruiting→Active, Not Recruiting Study Status, Contacts/Locations v2
Trial statusRecruiting→Active, Not Recruiting
Primary completion dateestimated 2024-04→confirmed 2025-09-09
Completion date2026-04→2027-06-11
Study sitesdetails revised at 1 of 1 site
2023-10-13
Not Yet Recruiting→Recruiting Study Status, Sponsor/Collaborators, Study Description, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locations, References, Document Section v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2023-05→confirmed 2023-05-12
Study sites0→1
Eligibility criteria-18 characters
[...] Participants of childbearing potential) Exclusion Criteria: • Patients that are not able to comply with all study visits P [...] ovid cannot be started immediately after discontinuation of any of the followingsuch medicinal products due to the delayed offset of the recentl [...]
Secondary endpoints7 to 9 entries
Risk factors for long-COVID Symptoms of long-COVID
Study description-1 characters
[...] ant medication contraindicated for the treatment of Paxlovid* Not currently pregnant or lactating Willingness to take a p [...]
Collaborators1 to 5 entries
Oslo University Hospital University of Oslo St. Olavs Hospital Norwegian University of Science and Technology
Publications12 to 13 entries
Ertesvag NU, Iversen A, Blomberg B, Ozgumus T, Rijal P, Fjelltveit EB, Cox RJ, Langeland N; Bergen COVID-19 research group. Post COVID-19 condition after delta infection and omicron reinfection in children and adolescents. EBioMedicine. 2023 Jun;92:104599. doi: 10.1016/j.ebiom.2023.104599. Epub 2023 [...]
2023-05-09
Original filing
The goal of this clinical trial is to compare treatment with oral Paxlovid (nirmatrelvir/ritonavir) and placebo for acute COVID-19 as an intervention to prevent long-COVID (post-COVID-19 condition) in adults aged 18-64 years old. The main question it aims to answer is: Does treatment with Paxlovid for acute COVID-19 reduce the prevalence of long-COVID compared to placebo. Participants with acute COVID-19, documented with positive lateral flow test or PCR, within the last 5 days will be randomised to take either Paxlovid or placebo. All participants will receive standard of care in addition. Participants will respond to electronic questionnaires at 14 time points during follow-up. The primary outcome is presence of long-COVID symptoms at 3 months follow-up. Researchers will compare participants who received Paxlovid and placebo to see if Paxlovid treatment can prevent the occurrence of long-COVID.
Trial Details
NCT Number NCT05852873
Lead Sponsor Haukeland University Hospital
Collaborators: University of Bergen, Oslo University Hospital, University of Oslo, St. Olavs Hospital, Norwegian University of Science and Technology
Conditions Post COVID-19 Condition, Unspecified, SARS-CoV2 Infection, COVID-19
Enrollment 2,000 participants
Start Date 2023-05-12
Primary Completion 2025-09-09 (estimated)
Study Completion 2027-06-11 (estimated)
Updated on ClinicalTrials.gov 2025-11-21